cAMPfield Therapeutics

cAMPfield Therapeutics is a clinical-stage biopharmaceutical company focused on developing well-tolerated and highly effective oral medicines, founded and led by industry veterans with success developing therapies for immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD). 

Prifemilast is an investigational, potentially best-in-class, once-daily oral PDE4B-selective inhibitor designed to set a new standard of care for IBD. Prifemilast has been well-tolerated in more than 700 clinical trial participants to date and has demonstrated robust efficacy in a Phase 3 trial for plaque psoriasis, 

Many clinicians and patients prefer the convenience and familiarity of oral therapies, but currently approved oral treatments for IBD are limited by poor tolerability, safety concerns, or modest efficacy. Prifemilast offers the potential to combine the convenience of an oral therapy with the safety and efficacy that patients deserve.